Related Experiment Video
Updated: Jun 12, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[Chemoradiation in bladder cancer]
M Housset1, C Durdux, J Thariat
1Hôpital Européen Georges-Pompidou, Service d'onco-radiothérapie, AP-HP, 20, rue Leblanc, 75015 Paris, France. martin.housset@egp.aphp.fr <martin.housset@egp.aphp.fr>
Abstract:
Bladder cancer is the second most common urologic tumor after prostate cancer. Radical cystectomy is the standard treatment of localized muscle-invasive tumors. However, urinary diversion (using a conduit or continent diversion) following radical cystectomy can be debilitating. Moreover, delayed metastases appear frequently in spite of radical surgery. So, for selected patients, chemoradiotherapy is a valid therapeutic alternative to cystectomy. Cisplatin or derivatives are administered concurrently to radiation therapy up to 60-65 Gy. Patients undergo control cystoscopy at mid-course in treatment in order to select responders from non responders. This review summarizes the main published series of radiochemotherapy in invasive bladder cancer. Results for local control, survivals, bladder preservation rates and toxicity are presented.